New Drug Candidate Reverses Metabolic Liver Disease and Fibrosis

Why It Matters

MASH affects millions and currently lacks approved pharmacologic options, so a drug that reverses fibrosis while improving metabolic markers could transform treatment and reduce downstream complications such as liver cancer, heart disease, and transplantation.

Key Takeaways

• EVT0185 reverses fibrosis in mouse MASH models.
• Inhibits ACLY and ACSS2, curbing hepatic fat synthesis.
• Lowers blood glucose, cholesterol, and liver fat accumulation.
• Canada lacks approved MASH therapies; unmet clinical need.
• Phase‑1 trials expected by 2027 after toxicology.

Pulse Analysis

Metabolic dysfunction‑associated steatohepatitis (MASH) has emerged as a leading cause of chronic liver disease worldwide, driven by rising obesity and type‑2 diabetes rates. Patients typically receive lifestyle advice and dietary interventions, yet no pharmacologic therapy is approved in Canada, leaving a sizable unmet clinical need. The disease’s progression to fibrosis not only threatens liver function but also raises the risk of cardiovascular events, cancer, and the need for transplantation, underscoring the urgency for disease‑modifying treatments.

The experimental compound EVT0185 distinguishes itself by dual inhibition of ATP‑citrate lyase (ACLY) and acetyl‑CoA synthetase 2 (ACSS2), two enzymes central to de‑novo lipogenesis and fatty‑acid oxidation. In mouse models, this “carbon release valve” mechanism halted fat accumulation, normalized blood glucose and cholesterol, and, critically, reversed established hepatic fibrosis. Such multi‑target activity addresses the metabolic triad that fuels MASH, offering a therapeutic profile that extends beyond symptom management to true tissue regeneration.

If EVT0185 advances to human trials as planned for 2027, it could reshape the MASH treatment landscape and open a new market segment for metabolic‑liver therapeutics. Investors and pharmaceutical firms will watch the toxicology and Phase‑1 data closely, as successful outcomes may accelerate regulatory pathways in North America and Europe. Moreover, the drug’s potential crossover benefits for liver cancer and cardiovascular disease could broaden its commercial appeal, positioning Espervita Therapeutics as a pioneer in integrated metabolic‑organ health solutions.